eligibility_summary
Adults ≥18 with B7H3+ solid tumors and leptomeningeal (±brain) metastases, positive CSF cytology, ECOG ≤2/KPS ≥60, ≥8‑week life expectancy, adequate marrow/liver/kidney/coagulation, agree to contraception and consent. Exclude: CNS RT <7 days, uncontrolled comorbidities, psych/substance issues, other investigational drugs, immunodeficiency, active infection, MRI inability, major CV disease, allergy to immunotherapy, prior CAR‑T/immune cells, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: QH104 Cell injection—an allogeneic, engineered cellular immunotherapy using B7-H3 (CD276)-targeted CAR-γδ T cells, given as local (meningeal/CSF) injections at 3×10^7 cells/dose, with optional repeat dosing ~every 2 weeks. Mechanism of action: The chimeric antigen receptor enables MHC-independent recognition of B7-H3 on tumor cells, CAR engagement activates T-cell signaling, leading to cytotoxic killing (perforin/granzyme) and cytokine release. γδ T cells add innate-like, stress-antigen recognition (e.g., via γδ TCR/NKG2D) and have lower alloreactivity, supporting an off‑the‑shelf approach. Targets: B7-H3+ tumor cells in meningeal/leptomeningeal metastases, key pathways include B7-H3/CD276 and CAR-mediated T-cell activation.